Domača stranEVGN • NASDAQ
add
Evogene Ltd
Prejšnji trg. dan.
0,94 $
Dnevni razpon
0,93 $ - 1,10 $
Letni razpon
0,93 $ - 2,42 $
Tržna kapitalizacija
9,58 mio. USD
Povprečni obseg
55,63 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 312,00 tis. | −82,63 % |
Stroški poslovanja | 2,88 mio. | −64,76 % |
Čisti dohodek | 3,87 mio. | 150,77 % |
Čista dobičkovnost prihodkov | 1,24 tis. | 392,27 % |
Earnings per share | −0,46 | 64,51 % |
EBITDA | −2,44 mio. | 64,22 % |
Efektivna davčna stopnja | −0,04 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 15,96 mio. | −20,02 % |
Skupna sredstva | 26,09 mio. | −34,97 % |
Skupne obveznosti | 8,83 mio. | −68,31 % |
Celoten lastniški kapital | 17,25 mio. | — |
Shares outstanding | 8,72 mio. | — |
Razmerje P/B | 7,23 | — |
Donosnost sredstev | −22,70 % | — |
Donosnost kapitala | −39,13 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 3,87 mio. | 150,77 % |
Denar iz dejavnosti | −3,33 mio. | 32,37 % |
Denar iz naložb | 10,91 mio. | 441,12 % |
Denar iz financiranja | −10,34 mio. | −318,34 % |
Neto sprememba denarnih sredstev | −2,70 mio. | −247,46 % |
Prost denarni tok | −385,62 tis. | −131,18 % |
Vizitka
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
Generalni direktor
Datum ustanovitve
1999
Spletno mesto
Zaposleni
117
